CD274 and non-small cell lung carcinoma: Realizing the dearth of reliable metastatic squamous or non-squamous NSCLC therapies, Zhou and colleagues [257] examined the efficacy of sugemalimab (a PD-L1 inhibitor) combined with chemotherapy on metastatic squamous or non-squamous NSCLC patients via randomized, phase III clinical trial, GEMSTONE-302.